4D Molecular Therapeutics (FDMT) Insider Trading & Ownership $5.93 +0.10 (+1.72%) As of 04:38 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$16.38 M Get FDMT Insider Trade Alerts Want to know when executives and insiders are buying or selling 4D Molecular Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FDMT Insider Buying and Selling by Quarter Ad Brownstone ResearchElon Musk’s next tweet could help pay for your retirementElon Musk says the government is going bankrupt. Seniors are getting crushed by inflation. But there is a way you could claim a chunk of over $1 trillion in spending, courtesy of Elon Musk. 4D Molecular Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/16/2024Scott BizilyInsiderSell500$16.33$8,165.00 7/16/2024Scott BizilyInsiderSell1,750$27.11$47,442.50 7/11/2024Scott BizilyInsiderSell1,996$25.00$49,900.00 7/10/2024David KirnCEOSell12,923$22.49$290,638.27 7/1/2024Scott BizilyInsiderSell4,248$21.36$90,737.28 6/24/2024David KirnCEOSell12,930$23.10$298,683.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/16/2024Scott BizilyInsiderSell1,750$25.45$44,537.50 4/16/2024Scott BizilyInsiderSell1,750$25.74$45,045.00 4/1/2024Scott BizilyInsiderSell8,153$31.78$259,102.34 3/27/2024Scott BizilyInsiderSell5,833$35.04$204,388.32 3/18/2024Scott BizilyInsiderSell1,750$31.27$54,722.50 2/27/2024Scott BizilyInsiderSell1,909$30.00$57,270.00 2/16/2024Scott BizilyInsiderSell1,750$27.67$48,422.50 2/8/2024David KirnCEOSell92,001$27.13$2,495,987.13 2/8/2024Scott BizilyInsiderSell6,244$27.50$171,710.00 2/5/2024Robert Young KimInsiderSell24,552$30.05$737,787.60 1/23/2024David KirnCEOSell5,696$18.41$104,863.36 1/4/2024David KirnCEOSell40,732$20.31$827,266.92 1/4/2024Global Investors Lp VikingMajor ShareholderSell540,000$19.53$10,546,200.00 (Data available from 1/1/2013 forward) FDMT Insider Trading Activity - Frequently Asked Questions Who is on 4D Molecular Therapeutics's Insider Roster? The list of insiders at 4D Molecular Therapeutics includes David Kirn, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim, and Scott Bizily. Learn more on insiders at FDMT. What percentage of 4D Molecular Therapeutics stock is owned by insiders? 7.30% of 4D Molecular Therapeutics stock is owned by insiders. Learn more on FDMT's insider holdings. Which 4D Molecular Therapeutics insiders have been buying company stock? The following insider purchased FDMT shares in the last 24 months: Global Investors Lp Viking ($13,600,000.00). How much insider buying is happening at 4D Molecular Therapeutics? Insiders have purchased a total of 850,000 FDMT shares in the last 24 months for a total of $13,600,000.00 bought. Which 4D Molecular Therapeutics insiders have been selling company stock? The following insiders have sold FDMT shares in the last 24 months: David Kirn ($4,612,962.77), Global Investors Lp Viking ($10,546,200.00), Jacob Chacko ($100,250.00), Robert Young Kim ($737,787.60), and Scott Bizily ($1,319,159.41). How much insider selling is happening at 4D Molecular Therapeutics? Insiders have sold a total of 812,358 4D Molecular Therapeutics shares in the last 24 months for a total of $17,316,359.78 sold. 4D Molecular Therapeutics Key ExecutivesDr. John F. Milligan Ph.D. (Age 63)Executive Chairman Compensation: $150kDr. David H. Kirn M.D. (Age 61)Co-Founder, CEO & Director Compensation: $1.01MDr. Fariborz Kamal Ph.D. (Age 61)President & COO Compensation: $786.2kDr. Noriyuki Kasahara M.D. (Age 61)Ph.D., Chief Scientific Officer Compensation: $201.29kDr. Robert Y. Kim M.B.A. (Age 63)M.D., Chief Medical Officer Compensation: $704.84kMs. Theresa Janke (Age 49)Co-Founder & Chief of Staff Compensation: $652.32kMr. Uneek Mehra (Age 52)Chief Financial & Business Officer Dr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal Officer & Corporate Secretary Dr. An Song Ph.D.Chief Development OfficerDr. Alan H. Cohen FAAAAI (Age 63)FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology More Insider Trading Tools from MarketBeat Related Companies BCYC Insider Trades BCAX Insider Trades AVXL Insider Trades COLL Insider Trades AVBP Insider Trades PSTX Insider Trades NUVB Insider Trades REPL Insider Trades QURE Insider Trades PAHC Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop BuyingAppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the Millions This page (NASDAQ:FDMT) was last updated on 1/3/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.